Repatha vs Praluent: What to Do When One Fails

How Evolocumab and Alirocumab Work, and Why They Are Not Interchangeable on Paper

Both drugs bind PCSK9, a serine protease that tags hepatic LDL receptors for degradation. Blocking PCSK9 preserves LDL receptors on the liver surface, accelerating LDL particle clearance from the bloodstream [1]. The mechanism is identical. The molecules themselves differ in binding epitope, dosing intervals, and device design, which is why a patient who tolerates one imperfectly may respond differently to the other.

Molecular Differences That Matter Clinically

Evolocumab is a fully human IgG2 monoclonal antibody approved at 140 mg every 2 weeks or 420 mg once monthly [2]. Alirocumab is a fully human IgG1 monoclonal antibody approved at 75 mg or 150 mg every 2 weeks, with a 300 mg monthly option added post-approval [3]. The IgG subclass difference is minor pharmacologically, but it may influence rare immunogenicity patterns in individual patients.

Delivery Device Differences

Evolocumab's 420 mg monthly dose is delivered via a prefilled single-use autoinjector or a 3-cartridge SureClick device. Alirocumab's 300 mg monthly dose uses a single 2 mL prefilled pen. Patients with injection anxiety or dexterity limitations sometimes prefer one format over the other. Device preference alone can justify a switch.

The Cardiovascular Outcome Trial Evidence for Each Drug

The two agents have separate dedicated cardiovascular outcome trials, not a head-to-head comparison. Understanding the numbers from each trial helps set realistic expectations after switching.

FOURIER: Evolocumab in Secondary Prevention

FOURIER enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) on optimized statin therapy [4]. Evolocumab 140 mg every 2 weeks or 420 mg monthly reduced LDL-C from a median baseline of 92 mg/dL to 30 mg/dL, a 59% reduction. The primary composite endpoint (CV death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group vs 11.3% placebo over a median 2.2 years, a relative risk reduction of 15% (P<0.001) [4]. Myocardial infarction risk fell by 27% and stroke risk by 21%.

ODYSSEY OUTCOMES: Alirocumab After Acute Coronary Syndrome

ODYSSEY OUTCOMES enrolled 18,924 patients 1 to 12 months after an acute coronary syndrome (ACS) event, all on high-intensity statin therapy [5]. Alirocumab was titrated from 75 mg to 150 mg every 2 weeks if LDL-C remained above 50 mg/dL at 8 weeks. The primary endpoint (coronary heart disease death, non-fatal MI, ischemic stroke, or unstable angina requiring hospitalization) occurred in 9.5% alirocumab vs 11.1% placebo, a 15% relative risk reduction (P<0.001) [5]. In patients with baseline LDL-C at or above 100 mg/dL, the absolute risk reduction was 3.4 percentage points.

What the Trials Do Not Tell Us About Switching

Neither FOURIER nor ODYSSEY OUTCOMES studied patients who crossed over from one PCSK9 inhibitor to the other after failure. The switching data come from smaller observational studies and pharmacokinetic reasoning, not large outcome trials. A 2022 real-world registry analysis published in the Journal of Clinical Lipidology found that roughly 60% of patients who switched PCSK9 inhibitors due to inadequate LDL response achieved the target LDL-C goal on the second agent within 12 weeks [6]. That number is not from a randomized trial, but it is the best available evidence for the switch scenario.

When to Consider Switching from Repatha to Praluent, or Vice Versa

A switch is clinically reasonable in four specific situations. Each has a different underlying mechanism and a different expected benefit.

1. Inadequate LDL-C Response

Both drugs should lower LDL-C by roughly 50 to 60% from baseline [4,5]. If a patient on maximally tolerated statin plus evolocumab at 140 mg every 2 weeks still has LDL-C above 70 mg/dL for secondary prevention (or above 55 mg/dL for very high-risk patients per the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction), the first step is to confirm adherence and injection technique [7]. If those are confirmed, switching to alirocumab and titrating to 150 mg every 2 weeks may yield a modestly different response due to binding epitope differences. The ACC/AHA 2022 guideline states: "For patients with clinical ASCVD at very high risk who require additional LDL-C lowering, a PCSK9 inhibitor is recommended if the LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe therapy" [7].

2. Injection-Site Reactions or Local Tolerability

Injection-site reactions occurred in 2.1% of evolocumab patients in FOURIER vs 1.8% placebo [4] and in 3.8% of alirocumab patients in ODYSSEY OUTCOMES vs 2.1% placebo [5]. When reactions are persistent and bothersome, switching devices and molecules can reduce local inflammation driven by formulation excipients rather than the antibody itself.

3. Formulary Access and Out-of-Pocket Cost

In the United States, prior authorization requirements differ between payers and between the two drugs. A patient denied coverage for one may be approved for the other under a different formulary tier or manufacturer copay assistance program. Both Amgen (Repatha) and Sanofi/Regeneron (Praluent) operate patient assistance programs for uninsured or underinsured patients. Formulary switches driven by cost are the most common real-world reason for switching, according to pharmacy claims data [6].

4. Dosing Schedule Preference

Alirocumab's 300 mg monthly option (approved by the FDA in 2019 [3]) gives patients a once-monthly injection at the same clinical efficacy as biweekly 150 mg dosing. If a patient on evolocumab 140 mg every 2 weeks finds the biweekly schedule burdensome and cannot tolerate the 420 mg monthly volume, switching to alirocumab 300 mg monthly provides an equivalent schedule with a single 2 mL injection instead of three 1.4 mL cartridges.

How to Execute the Switch: A Step-by-Step Protocol

Switching between PCSK9 inhibitors does not require a washout period. Both agents have elimination half-lives of approximately 11 to 17 days [2,3], so the outgoing drug's effect fades naturally while the incoming drug takes effect. The practical protocol below is consistent with current lipidology practice and FDA labeling.

Step 1: Confirm the Reason for Switching

Document the primary failure mode: inadequate LDL-C response (get a fasting lipid panel first), injection-site intolerance, adherence failure, or formulary/cost barrier. Each reason changes downstream monitoring expectations.

Step 2: Write the New Prescription on the Day of the Last Dose

No gap is needed. Prescribe the new agent to start on the same day the last dose of the old agent was scheduled, or within 7 days afterward. Starting alirocumab at 75 mg every 2 weeks is appropriate for most patients; titrate to 150 mg at week 8 if the repeat lipid panel shows LDL-C above 50 to 70 mg/dL depending on risk category.

Step 3: Re-measure LDL-C at 4 to 8 Weeks

A fasting lipid panel at 4 weeks confirms the new drug is active. Full steady-state LDL-C reduction is typically reached by 8 weeks. Compare the result against the patient's individualized LDL-C target from the ACC/AHA guideline, which sets a goal below 70 mg/dL for most secondary prevention patients and below 55 mg/dL for very high-risk patients (recent ACS within 12 months, two or more major ASCVD events, or ASCVD plus diabetes plus hypertension plus LDL-C 100 mg/dL or higher) [7].

Step 4: Add Ezetimibe If the Second PCSK9 Inhibitor Also Falls Short

Ezetimibe 10 mg daily added to a PCSK9 inhibitor provides an additional 15 to 20% LDL-C reduction [8]. The IMPROVE-IT trial (N=18,144) showed that adding ezetimibe to simvastatin reduced the composite CV endpoint by 6.4% relative to simvastatin alone over 7 years (P=0.016) [8]. If a patient fails two sequential PCSK9 inhibitors, inclisiran (Leqvio) or bempedoic acid (Nexletol) are the next considerations, not a third antibody.

Comparing Efficacy Numbers Side by Side

The table below uses published trial data. Both agents are compared against placebo on a background of maximally tolerated statin therapy. There is no approved head-to-head trial between evolocumab and alirocumab.

| Parameter | Evolocumab (FOURIER) | Alirocumab (ODYSSEY OUTCOMES) | |---|---|---| | N enrolled | 27,564 | 18,924 | | Baseline LDL-C (median) | 92 mg/dL | 87 mg/dL | | On-treatment LDL-C (median) | 30 mg/dL | 53 mg/dL (75 mg arm) / 48 mg/dL (150 mg arm) | | LDL-C reduction from baseline | 59% | 54 to 62% depending on dose | | Primary endpoint RRR | 15% | 15% | | Follow-up duration | 2.2 years | 2.8 years | | All-cause mortality reduction | Not significant at 2.2 years | Significant in high-LDL subgroup (P=0.026) [5] |

The near-identical 15% relative risk reduction across both trials supports treating the two drugs as clinically equivalent for most patients in terms of expected outcomes. Population differences (ACS cohort vs stable ASCVD) limit direct numerical comparison.

Safety Profile Comparison

Both drugs have comparable safety profiles in their respective trials. Neurocognitive events (confusion, memory impairment) were studied in the EBBINGHAUS substudy of FOURIER (N=1,974) and showed no difference vs placebo on the Cambridge Neuropsychological Test Automated Battery at 19 months [9]. Alirocumab showed no signal for neurocognitive harm in the ODYSSEY OUTCOMES safety analysis [5].

New-Onset Diabetes Risk

Neither drug increases new-onset diabetes risk. Evolocumab showed no difference in diabetes incidence vs placebo in FOURIER [4]. Alirocumab similarly showed no increase in ODYSSEY OUTCOMES [5]. This distinguishes PCSK9 inhibitors from statins, which carry an FDA label warning for modest increased risk of hyperglycemia.

Muscle-Related Side Effects

PCSK9 inhibitors do not cause myopathy. The musculoskeletal adverse event rate in FOURIER was 8.2% evolocumab vs 7.9% placebo [4], a non-significant difference. Patients who stopped statins due to myalgia and are now on PCSK9 monotherapy tolerate both agents well.

Antibody Formation

Anti-drug antibody (ADA) formation occurred in 0.1% of evolocumab patients in FOURIER and in 1.2% of alirocumab patients in ODYSSEY OUTCOMES [4,5]. Neither rate caused clinically meaningful loss of efficacy in the trial populations. ADA development is a rare but documented reason why an individual patient might lose LDL-C response over time, and it theoretically could explain why switching to the other antibody restores efficacy.

Special Populations: Who Benefits Most from Switching

Heterozygous Familial Hypercholesterolemia (HeFH)

Patients with HeFH have baseline LDL-C levels often exceeding 190 mg/dL despite maximum statin therapy. Both evolocumab and alirocumab carry FDA approval for HeFH [2,3]. In a 52-week randomized trial of evolocumab in HeFH patients (RUTHERFORD-2, N=331), evolocumab 140 mg every 2 weeks reduced LDL-C by 59.2% vs 0.5% placebo (P<0.001) [10]. If a HeFH patient does not reach an LDL-C below 100 mg/dL on one agent, switching and adding ezetimibe is the recommended next step before considering LDL apheresis.

Post-ACS Patients

ODYSSEY OUTCOMES specifically enrolled post-ACS patients, making alirocumab the agent with the strongest direct evidence in that setting [5]. The trial also showed a statistically significant reduction in all-cause mortality in patients with baseline LDL-C at or above 100 mg/dL (HR 0.71, 95% CI 0.56 to 0.90) [5]. If a post-ACS patient was started on evolocumab but has inadequate LDL response, switching to alirocumab 150 mg every 2 weeks aligns with the population most studied in ODYSSEY OUTCOMES.

Statin-Intolerant Patients

FDA approved both drugs as monotherapy (without a statin) for patients with primary hyperlipidemia who cannot tolerate any statin dose [2,3]. In this group, PCSK9 inhibitor monotherapy reduces LDL-C by approximately 40 to 50% from an often-elevated baseline, less than the 50 to 60% seen on background statin. If one agent provides insufficient LDL-C reduction as monotherapy, the combination of the alternative PCSK9 inhibitor plus ezetimibe (no statin) may reach target.

Cost, Access, and Practical Formulary Navigation

The 2024 average wholesale price for evolocumab 140 mg/mL is approximately $657 per pen, and alirocumab 150 mg/mL lists at approximately $610 per pen, though net prices after rebates are substantially lower and vary by insurer. Both manufacturers offer copay cards reducing out-of-pocket costs to as low as $5, $10 per month for commercially insured patients.

Medicare Part D beneficiaries face different rules. The Inflation Reduction Act of 2022 caps out-of-pocket drug costs for Medicare beneficiaries at $2,000 annually starting in 2025, which meaningfully reduces the financial burden for this high-risk population. When a patient's Part D plan does not cover one agent, checking formulary status for the alternative is always the first practical step before initiating a prior authorization appeal.

The ACC/AHA 2022 guideline explicitly states: "A clinician-patient discussion about the potential for a net benefit and drug cost is recommended before initiating PCSK9 inhibitor therapy" [7]. That same conversation applies when considering a switch.

Monitoring After the Switch

Re-check a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C) 4 weeks after the first injection of the new agent. A second panel at 8 to 12 weeks confirms steady-state response. If LDL-C target is not reached at 8 weeks on alirocumab 75 mg, titrate to 150 mg. Annual lipid panels are sufficient for stable responders. Liver function tests and creatine kinase are not routinely required for PCSK9 inhibitors, unlike statin monitoring.

Document the switch reason in the medical record to support prior authorization for the new agent. Most payers require documentation of a failure reason and confirmation of maximally tolerated statin therapy before approving either PCSK9 inhibitor.